Form 4: Black Diamond Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director Prakash Raman acquires 6,848 shares of Black Diamond Therapeutics (BDTX) common stock at $1.88 per share in lieu of cash compensation.

Summary

• On March 21, 2025, Prakash Raman, a director of Black Diamond Therapeutics, Inc. (BDTX), acquired 6,848 shares of common stock.
• The shares were issued as part of the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy.
• Raman elected to receive shares of BDTX common stock instead of cash compensation for annual services as a non-employee director.
• The acquisition price was $1.88 per share, based on the closing market price of BDTX common stock on March 20, 2025.
• Following the transaction, Raman directly owns 16,993 shares of BDTX.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a standard compensation practice. The director taking shares instead of cash is a mildly positive signal.

Positives

• The director's decision to take shares in lieu of cash demonstrates confidence in the company's future prospects.

Industry Context

This is a routine transaction related to director compensation and is common practice in publicly traded companies.

Related Party Transactions

• The issuance of shares to Prakash Raman, a director, in lieu of cash compensation is a related party transaction.

Stakeholder Impact

• The transaction has a minor dilutive effect on existing shareholders.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Director, Prakash Raman, Share Acquisition, Form 4, Director Compensation, Equity, Securities